Get Premium to unlock powerful stock data

NAS:ORGS (USA) Healthcare » Biotechnology

Orgenesis Inc $ 2.60 0.1 (4%)

Volume:

14,607

Avg Vol (1m):

90,135

Market Cap $:

63.12 Mil

Enterprise Value $:

58.64 Mil

PE Ratio:

At Loss

PB Ratio:

1.48

Also Trade In: Germany

EMBED

10Y: -% Above Low: +NaN% Below High: NaN%

Peers

View Full Chart

What is PE Ratio (TTM)?

Current and historical daily P/E ratio for Orgenesis Inc () from 2010 to Jan 26 2022. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Orgenesis stock (ORGS) PE ratio as of Jan 26 2022 is 0. More Details

Orgenesis PE Ratio (TTM) Chart

EMBED

Orgenesis PE Ratio (TTM) Historical Data

View and export this data going back to 2010. Start your Free Trial

Total 1245

Orgenesis PE Ratio (TTM) Historical Data
Date	PE Ratio (TTM) Data	Date	PE Ratio (TTM) Data
2022-01-26	At Loss	2021-11-24	At Loss
2022-01-25	At Loss	2021-11-23	At Loss
2022-01-24	At Loss	2021-11-22	At Loss
2022-01-21	At Loss	2021-11-19	At Loss
2022-01-20	At Loss	2021-11-18	At Loss
2022-01-19	At Loss	2021-11-17	At Loss
2022-01-18	At Loss	2021-11-16	At Loss
2022-01-17	At Loss	2021-11-15	At Loss
2022-01-14	At Loss	2021-11-12	At Loss
2022-01-13	At Loss	2021-11-11	At Loss
2022-01-12	At Loss	2021-11-10	At Loss
2022-01-11	At Loss	2021-11-09	At Loss
2022-01-10	At Loss	2021-11-08	At Loss
2022-01-07	At Loss	2021-11-05	At Loss
2022-01-06	At Loss	2021-11-04	At Loss
2022-01-05	At Loss	2021-11-03	At Loss
2022-01-04	At Loss	2021-11-02	At Loss
2022-01-03	At Loss	2021-11-01	At Loss
2021-12-31	At Loss	2021-10-29	At Loss
2021-12-30	At Loss	2021-10-28	At Loss
2021-12-29	At Loss	2021-10-27	At Loss
2021-12-28	At Loss	2021-10-26	At Loss
2021-12-27	At Loss	2021-10-25	At Loss
2021-12-24	At Loss	2021-10-22	At Loss
2021-12-23	At Loss	2021-10-21	At Loss
2021-12-22	At Loss	2021-10-20	At Loss
2021-12-21	At Loss	2021-10-19	At Loss
2021-12-20	At Loss	2021-10-18	At Loss
2021-12-17	At Loss	2021-10-15	At Loss
2021-12-16	At Loss	2021-10-14	At Loss
2021-12-15	At Loss	2021-10-13	At Loss
2021-12-14	At Loss	2021-10-12	At Loss
2021-12-13	At Loss	2021-10-11	At Loss
2021-12-10	At Loss	2021-10-08	At Loss
2021-12-09	At Loss	2021-10-07	At Loss
2021-12-08	At Loss	2021-10-06	At Loss
2021-12-07	At Loss	2021-10-05	At Loss
2021-12-06	At Loss	2021-10-04	At Loss
2021-12-03	At Loss	2021-10-01	At Loss
2021-12-02	At Loss	2021-09-30	At Loss
2021-12-01	At Loss	2021-09-29	At Loss
2021-11-30	At Loss	2021-09-28	At Loss
2021-11-29	At Loss	2021-09-27	At Loss
2021-11-26	At Loss	2021-09-24	At Loss
2021-11-25	At Loss	2021-09-23	At Loss

Orgenesis PE Ratio (TTM) Comparison

Company	Market Cap(Mil)	PE Ratio (TTM)

Business Description

Industry

Healthcare » Biotechnology » NAICS : 325412 SIC : 2834

Traded in other countries / regions

45O.Germany ORGS.USA

Address

20271 Goldenrod Lane, Germantown, MD, USA, 20876

Website

https://www.orgenesis.com

Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.

Product

Business

Information

About

Affiliate Program

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names

Earn affiliate commissions by embedding GuruFocus Charts

GuruFocus Affiliate Program: Earn up to $400 per referral. Detailed

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.